AstraZeneca: CHMP Recommends Lynparza And Imfinzi Combination For EU Approval In Endometrial Cancer
(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) announced Monday that Imfinzi (durvalumab) and Lynparza (olaparib) have been recommended ...
Read moreDetails